Factor IX Deficiency
6
2
2
2
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
16.7%
1 terminated out of 6 trials
66.7%
-19.8% vs benchmark
0%
0 trials in Phase 3/4
50%
1 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (6)
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
The European Paediatric Network for Haemophilia Management ( PedNet Registry)
Natural History Study of Factor IX Treatment and Complications
A Study Comparing Factor Level and Inhibitor Titer Testing Results Drawn From Central Venous Lines and Venipuncture
An Institutional Pilot Study to Investigate Physical Activity Patterns in Boys With Hemophilia
Phase I/II Study of Monoclonal Factor IX Concentrate for Factor IX Deficiency